Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors

Nucleic Acids Research

Volumn 36, Issue 5, 2008, Pages 1482-1496

  Kaushik Basu, Neerja ^a   Bopda Waffo, Alain ^a   Talele, Tanaji T ^b   Basu, Amartya ^a   Costa, Paulo R R ^c   Da Silva, Alcides J M ^c   Sarafianos, Stefan G ^d   Noël, François ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; COUMESTAN DERIVATIVE; FLAVONOID; LQB 16; LQB 34; LQB 93; LQB 96; NUCLEOSIDE TRIPHOSPHATE; PHYTOESTROGEN; PROTON; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA; WEDELOLACTONE;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; BINDING KINETICS; CARBON NUCLEAR MAGNETIC RESONANCE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME SUBSTRATE; HEPATITIS C VIRUS; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RNA REPLICATION; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; BINDING, COMPETITIVE; COUMARINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; FLAVONOIDS; HYDROPHOBICITY; KINETICS; MODELS, MOLECULAR; PHYTOESTROGENS; RECOMBINANT PROTEINS; RNA; RNA REPLICASE; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 41149136756     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkm1178     Document Type: Article

References (70)

1. Choo,Q.L., Kuo,G., Weiner,A.J., Overby,L.R., Bradley,D.W. and Houghton,M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244, 359-362.
2. Seeff,L.B. (1999) Natural history of hepatitis C. Am. J. Med., 107, 10S-15S.
3. Di Bisceglie,A.M., Order,S.E., Klein,J.L., Waggoner,J.G., Sjogren,M.H., Kuo,G., Houghton,M., Choo,Q.L. and Hoofnagle,J.H. (1991) The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am. J. Gastroenterol., 86, 335-338.
4. WHO. (1999) Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat., 6, 35-47.
5. Armstrong,G.L., Wasley,A., Simard,E.P., McQuillan,G.M., Kuhnert,W.L. and Alter,M.J. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med., 144, 705-714.
6. Myles,D.C. (2001) Recent advances in the discovery of small molecule therapies for HCV. Curr. Opin. Drug Discov. Devel., 4, 411-416.
7. Dillon,J.F. (2004) Hepatitis C: What is the best treatment? J. Viral Hepat., 11(Suppl. 1), 23-27.
8. Ni,Z.J. and Wagman,A.S. (2004) Progress and development of small molecule HCV antivirals. Curr. Opin. Drug Discov. Devel., 7, 446-459.
9. Lauer,G.M. and Walker,B.D. (2001) Hepatitis C virus infection. N. Engl. J. Med., 345, 41-52.
10. Cornberg,M., Huppe,D., Wiegand,J., Felten,G., Wedemeyer,H. and Manns,M.P. (2003) Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3. Z. Gastroenterol., 41, 517-522.
11. Ideo,G. and Bellobuono,A. (2002) New therapies for the treatment of chronic hepatitis C. Curr. Pharm. Des., 8, 959-966.
12. Reichard,O., Norkrans,G., Fryden,A., Braconier,J.H., Sonnerborg,A. and Weiland,O. (1998) Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group. Lancet, 351, 83-87.
13. Arataki,K., Kumada,H., Toyota,K., Ohishi,W., Takahashi,S., Tazuma,S. and Chayama,K. (2006) Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy. Intervirology, 49, 352-361.
14. Farci,P., Quinti,I., Farci,S., Alter,H.J., Strazzera,R., Palomba,E., Coiana,A., Cao,D., Casadei,A.M., Ledda,R. et al. (2006) Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl Acad. Sci. USA 103, 8475-8480.
15. Pawlotsky,J.M. (2006) Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol., 299, 261-284.
16. Reed,K.E. and Rice,C.M. (2000) Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol., 242, 55-84.
17. De Francesco,R., Tomei,L., Altamura,S., Summa,V. and Migliaccio,G. (2003) Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS34A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res., 58, 1-16.
18. Behrens,S.E., Tomei,L. and De Francesco,R. (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J., 15, 12-22.
19. Adachi,T., Ago,H., Habuka,N., Okuda,K., Komatsu,M., Ikeda,S. and Yatsunami,K. (2002) The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. Biochim. Biophys. Acta, 1601, 38-48.
20. Ferrari,E., Wright-Minogue,J., Fang,J.W., Baroudy,B.M., Lau,J.Y. and Hong,Z. (1999) Characterization soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 73, 1649-1654.
21. Yamashita,T., Kaneko,S., Shirota,Y., Qin,W., Nomura,T., Kobayashi,K. and Murakami,S. (1998) RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NSSB protein truncated at the C-terminal region. J. Biol. Chem., 273, 15479-15486.
22. Yuan,Z.H., Kumar,U., Thomas,H.C., Wen,Y.M. and Monjardino,J. (1997) Expression, purification, and partial characterization of HCV RNA polymerase. Biochem. Biophys. Res. Commun., 232, 231-235.
23. Ishii,K., Tanaka,Y., Yap,C.C., Aizaki,H., Matsuura,Y. and Miyamura,T. (1999) Expression of hepatitis C virus NS5B protein: Characterization of its RNA polymerase activity and RNA binding. Hepatology, 29, 1227-1235.
24. Tomei,L., Vitale,R.L., Incitti.I., Serafini,S., Altamura,S., Vitelli,A. and De Francesco,R. (2000) Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J. Gen. Virol., 81, 759-767.
25. Ago,H., Adachi,T., Yoshida,A., Yamamoto,M., Habuka,N., Yatsunami,K. and Miyano,M. (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure, 7, 1417-1426.
26. Bressanelli,S., Tomei,L., Roussel,A., Incitti,I., Vitale,R.L., Mathieu,M., De Francesco,R. and Rey,F.A. (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA, 96, 13034-13039.
27. Lesburg,C.A., Cable,M.B., Ferrari,E., Hong,Z., Mannarino,A.F. and Weber,P.C. (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol., 6, 937-943.
28. Luo,G., Hamatake,R.K., Mathis,D.M., Racela,J., Rigat,K.L., Lemm,J. and Colonno,R.J. (2000) De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J. Virol. 74, 851-863.
29. Zhong,W., Ferrari,E., Lesburg,C.A., Maag,D., Ghosh,S.K., Cameron,C.E., Lau,J.Y. and Hong,Z. (2000) Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. J. Virol., 74, 9134-9143.
30. Lohmann,V., Overton,H. and Bartenschlager,R. (1999) Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. J. Biol. Chem., 274, 10807-10815.
31. Dhanak,D., Duffy,K.J., Johnston,V.K., Lin-Goerke,J., Darcy,M., Shaw,A.N., Gu,B., Silverman,C., Gates,A.T., Nonnemacher,M.R. et al. (2002) Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem., 277, 38322-38327.
32. Gu,B., Johnston,V.K., Gutshall,L.L., Nguyen,T.T., Gontarek,R.R., Darcy,M.G., Tedesco,R., Dhanak,D., Duffy,K.J., Kao,C.C. et al. (2003) Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J. Biol. Chem., 278, 16602-16607.
33. Chan,L., Reddy,T.J., Proulx,M., Das,S.K., Pereira,O., Wang,W., Siddiqui,A., Yannopoulos,C.G., Poisson,C., Turcotte,N. et al. (2003) Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. J. Med. Chem., 46, 1283-1285.
34. Carroll,S.S., Tomassini,J.E., Bosserman,M., Getty,K., Stahlhut,M.W., Eldrup,A.B., Bhat,B., Hall,D., Simcoe,A.L., LaFemina,R. et al. (2003) Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem., 278, 11979-11984.
35. Wang,M., Ng,K.K., Cherney,M.M., Chan,L., Yannopoulos,C.G., Bedard,J., Morin,N., Nguyen-Ba,N., Alaoui-Ismaili,M.H., Bethell,R.C. et al. (2003) Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem., 278, 9489-9495.
36. Beaulieu,P.L. and Tsantrizos,Y.S. (2004) Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs, 5, 838-850.
37. Walker,M.P., Yao,N. and Hong,Z. (2003) Promising candidates for the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs, 12, 1269-1280.
38. Mors,W.B., do Nascimento,M.C., Parente,J.P., da Silva,M.H., Melo,P.A. and Suarez-Kurtz,G. (1989) Neutralization of lethal and myotoxic activities of South American rattlesnake venom by extracts and constituents of the plant Eclipta prostata(Asteraceae). Toxicon 27, 1003-1009.
39. Singh,B., Saxena,A.K., Chandan,B.K., Agarwal,S.G. and Anand,K.K. (2001) In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Indian J. Physiol. Pharmacol., 45, 435-441.
40. Horn-Ross,P.L., Barnes,S., Lee,M., Coward,L., Mandel,J.E., Koo,J., John,E.M. and Smith,M. (2000) Assessing phytoestrogen exposure in epidemiologic studies: Development of a database (United States). Cancer Causes Control, 11, 289-298.
41. da Silva,A.J.M., Mclo,P.A., Silva,N.M., Brito,F.V., Buarque,C.D., de Souza,D.V., Rodrigues,V.P., Pocas,E.S., Noel,F., Albuquerque,E.X. et al. (2001) Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg. Med. Chem. Lett., 11, 283-286.
42. Wagner,H., Geyer,B., Kiso,Y., Hikino,H. and Rao,G.S. (1986) Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulaceal. Planta Med., 52, 370-374.
43. Kobori,M., Yang,Z., Gong,D., Heissmeyer,V., Zhu,H., Jung,Y.K., Gakidis,M.A., Rao,A., Sekine,T., Ikegami,F. et al. (2004) Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ., 11, 123-130.
44. Pocas,E.S., Costa,P.R., da Silva,A.J. and Noel,F. (2003) 2-Methoxy-3,8,9-trihydroxy coumestan: A new synthetic inhibitor of Na+,K+-ATPase with an original mechanism of action. Biochem. Pharmacol., 66, 2169-2176.
45. Oh,J.W., Ito,T. and Lai,M.M. (1999) A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. J. Virol., 73, 7694-7702.
46. Vo,N.V., Oh,J.W. and Lai,M.M. (2003) Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology, 307 301-316.
47. Kaushik,N., Pandey,V.N. and Modak,M.J. (1996) Significance of the O-helix residues of Escherichia coli DNA polymerase I in DNA synthesis: Dynamics of the dNTP binding pocket. Biochemistry, 35, 7256-7266.
48. Kaushik,N., Rege,N., Yadav,P.N., Sarafianos,S.G., Modak,M.J. and Pandey,V.N. (1996) Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. Biochemistry, 35, 11536-11546.
49. Lee,G., Piper,D.E., Wang,Z., Anzola,J., Powers,J., Walker,N. and Li,Y. (2006) Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J. Mol. Biol., 357, 1051-1057.
50. Tomei,L., Altamura,S., Bartholomew,L., Biroccio,A., Ceccacci,A., Pacini,L., Narjes,F., Gennari,N., Bisbocci,M., Incitti,I. et al. (2003) Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol., 77, 13225-13231.
51. Vo,N.V,, Tuler,J.R. and Lai,M.M. (2004) Enzymatic characterization of the full-length and C-terminally truncated hepatitis C virus RNA polymerases: Function of the last 21 amino acids of the C terminus in template binding and RNA synthesis. Biochemistry, 43, 10579-10591.
52. McKercher,G., Beaulieu,P.L., Lamarre,D., LaPlante,S., Lefebvre,S., Pellerin,C., Thauvette,L. and Kukolj,G. (2004) Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/ primer substrate. Nucleic Acids Res., 32, 422-431.
53. Cornish-Bowden,A. (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem. J., 137, 143-144.
54. Jorgensen,W.L., Maxwell,D.S. and Tirado-Rives,J. (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc., 148, 11225-11236.
55. Bytheway,I. and Cochran,S. (2004) Validation of molecular docking calculations involving FGF-1 and FGF-2. J. Med. Chem., 47, 1683-1693.
56. Chen,H., Lyne,P.D., Giordanetto,F., Lovell,T. and Li,J. (2006) On evaluating molecular-docking methods for pose prediction and enrichment factors. J. Chem. Inf. Model., 46, 401-415.
57. Friesner,R.A., Banks,J.L., Murphy,R.B., Halgren,T.A., Klicic,J.J., Mainz,D.T., Repasky,M.P., Knoll,E.H., Shelley,M., Perry,J.K. et al. (2004) Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 47 1739-1749.
58. Halgren,T.A., Murphy,R.B., Friesner,R.A., Beard,H.S., Frye,L.L., Pollard,W.T. and Banks,J.L. (2004) Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem., 47, 1750-1759.
59. Ikegashira,K., Oka,T., Hirashima,S., Noji,S., Yamanaka,H., Hara,Y., Adachi,T., Tsuruha,J., Doi,S., Hase,Y. et al. (2006) Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J. Med. Chem., 49, 6950-6953.
60. Tedesco,R., Shaw,A.N., Bambal,R., Chai,D., Concha,N.O., Darcy,M.G., Dhanak,D., Fitch,D.M., Gates,A., Gerhardt,W.G et al. (2006) 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl) -4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem., 49, 971-983.
61. Kashiwagi,T., Hara,K., Kohara,M., Kohara,K., Iwahashi,J., Hamada,N., Yoshino,H. and Toyoda,T. (2002) Kinetic analysis of C-terminally truncated RNA-dependent RNA polymerase of hepatitis C virus. Biochem. Biophys. Res. Commun., 290, 1188-1194.
62. Liu,Y., Jiang,W.W., Pratt,J., Rockway,T., Harris,K., Vasavanonda,S., Tripathi,R., Pithawalla,R. and Kati,W.M. (2006) Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. Biochemistry, 45, 11312-11323.
63. Shi,Q., Singh,K., Srivastava,A., Kaushik,N. and Modak,M.J. (2002) Lysine 152 of MuLV reverse transcriptase is required for the integrity of the active site. Biochemistry, 41, 14831-14842.
64. Branca,F. and Lorenzetti,S. (2005) Health effects of phytoestrogens. Forum Nutr., 57, 100-111.
65. Humfrey,C.D. (1998) Phytoestrogens and human health effects: Weighing up the current evidence. Nat. Toxins, 6, 51-59.
66. Powers,J.P., Piper,D.E., Li,Y., Mayorga,V., Anzola,J., Chen,J.M., Jaen,J.C., Lee,G., Liu,J., Peterson,M.G. et al. (2006) SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem., 49, 1034-1046.
67. Beaulieu,P.L., Bos,M., Bousquet,Y., DeRoy,P., Fazal,G., Gauthier,J., Gillard,J., Goulet,S., McKercher,G., Poupart,M.A. et al. (2004) Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett., 14, 967-971.
68. Love,R.A., Parge,H.E., Yu,X., Hickey,M.J., Diehl,W., Gao,J., Wriggers,H., Ekker,A., Wang,L., Thomson,J.A. et al. (2003) Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77, 7575-7581.
69. Gopalsamy,A., Lim,K., Ciszewski,G., Park,K., Ellingboe,J.W., Bloom,J., Insaf,S., Upeslacis,J., Mansour,T.S., Krishnamurthy,G. et al. (2004) Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction. J. Med. Chem., 47, 6603-6608.
70. Tomei,L., Altamura,S., Bartholomew,L., Bisbocci,M., Bailey,C., Bosserman,M., Cellucci,A., Forte,E., Incitti,I., Orsatti,L. et al. (2004) Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol., 78, 938-946.